Why Is HIMS & HERS HEALTH I A (HIMS) Stock Up Today?

HIMS stock surged 7.56% to $34.08 on Thursday, snapping a three-day losing streak. The move followed news that the FDA added eight new panelists to its peptide advisory group. These panelists bring expertise in neurology, pain, dermatology, gastroenterology, addiction, cancer pharmacology, and patient advocacy. The development signals a potential shift in regulatory oversight and scrutiny of peptide therapies, which are central to Hims & Hers Health's business model.

The FDA's recent actions in the peptide space have been a focal point for the company. Earlier this week, the agency sent drug advertising warning letters to Hims & Others, as well as major players like Novo Nordisk and Eli Lilly. The addition of new, less conflicted panelists may indicate a more balanced and rigorous evaluation process for peptide-related products. This could influence how the company's offerings are perceived and regulated in the future.

The stock opened at $31.82 and reached an intraday high of $34.30 at 12:40 PM ET before settling at $34.13. Trading volume was 6.5 million shares, or 0.3 times the 3-month average. The stock has declined 8.5% over the past eight sessions, from $35.15 to $32.16. Recent insider activity shows a net outflow, with 8 sales totaling $3.9 million and only 1 buy totaling $1.2 million in the last 90 days. Unusual options activity included three notable prints, with call premiums totaling $1.0 million and put premiums at $443,000.

Investors should watch for further regulatory developments and any follow-up actions from the FDA, which could shape the trajectory of Hims & Hers Health stock in the near term.